[Metabolic therapy in neurology].

Area of Science:

• Neurology
• Endocrinology
• Pharmacology

Background:

• Brain ischemia and diabetic neuropathy are significant causes of morbidity.
• Effective therapeutic strategies for these conditions remain crucial.
• Rheosorbilact is an infusion drug based on polyalcohols.

Purpose of the Study:

• To evaluate the efficacy of rheosorbilact in the complex therapy of brain ischemia.
• To assess the effectiveness of rheosorbilact in managing diabetic neuropathy.
• To determine the impact of rheosorbilact on quality of life and specific clinical parameters.

Main Methods:

• Rheosorbilact administered intravenously (200-400 ml/day for 20 days).
• Quality of life assessed using the SF-36 scale.
• Neuropsychological tests, ultrasound duplex scanning, NRS pain scale, blood glucose, and electroneuromyography were employed.

Main Results:

• Significant improvement in quality of life observed post-treatment.
• Positive clinical effects noted in patients with brain ischemia and diabetic neuropathy.
• Changes in acid-base balance characteristics were also studied.

Conclusions:

• Rheosorbilact demonstrates significant clinical efficacy in patients with brain ischemia.
• Rheosorbilact is effective in the complex therapy of diabetic neuropathy.
• The drug offers a promising therapeutic option for improving patient outcomes.